
Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer
No efficacy-evaluable patients with invasive lobular breast carcinoma (n = 41) achieved a residual cancer burden (RCB) of 0 or 1 following treatment with first-line endocrine therapy combined with entrectinib (Rozlytrek), failing to meet the primary end …